AZD5363, a pan-AKT inhibitor, was reported to improve progression-free survival in advanced cancers with AKT1 mutations (18) However, the number of patients with MAC is too small to draw a conclusion on the pattern of AKT1, PIK3CA, TGFβ mutation. This evidence concerns the gene TGFB1 and cancer.